— Know what they know.
Not Investment Advice

IGC AMEX

IGC Pharma, Inc.
1W: -3.4% 1M: -17.7% 3M: +11.0% YTD: -0.7% 1Y: -10.6% 3Y: -12.4% 5Y: -78.9%
$0.29
-0.00 (-0.31%)
 
Weekly Expected Move ±8.1%
$0 $0 $0 $0 $0
AMEX · Healthcare · Biotechnology · Alpha Radar Sell · Power 35 · $28.8M mcap · 90M float · 1.20% daily turnover · Short 44% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$28.8M
52W Range0.24-0.5
Volume4,049,702
Avg Volume1,085,242
Beta0.50
Dividend
Analyst Ratings
2 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEORam Mukunda
Employees67
SectorHealthcare
IndustryBiotechnology
IPO Date2006-05-24
10224 Falls Road
Potomac, MD 20854
US
301 983 0998
About IGC Pharma, Inc.

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Recent Insider Trades

NameTypeSharesPriceDate
PRINS RICHARD K M-Exempt 70,000 2026-04-01
PRINS RICHARD K M-Exempt 100,000 2026-04-01
PRINS RICHARD K M-Exempt 70,000 2026-04-01
PRINS RICHARD K M-Exempt 100,000 2026-04-01
Mukunda Ram M-Exempt 323,077 $0.26 2026-04-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms